-

10:14:31 AM

ACHFF Stock News

ACHFF - Arch Biopartners, Inc.

08/05/22 7:30 AM

OTC : ACHFF

clinical trial

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor

RHEA-AI

neutral

02/14/22 7:30 AM

OTC : ACHFF

covid-19

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners Inc. (“Arch

RHEA-AI

neutral

02/03/22 7:30 AM

OTC : ACHFF

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal Science

RHEA-AI

neutral

01/04/22 7:25 AM

OTC : ACHFF

covid-19

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

Arch Biopartners Inc. (“Arch

RHEA-AI

neutral

12/01/21 7:35 AM

OTC : ACHFF

covid-19

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type. LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a

RHEA-AI

neutral

08/05/21 6:30 AM

OTC : ACHFF

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of

RHEA-AI

neutral

07/14/21 7:00 AM

OTC : ACHFF

Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch scientists have been awarded a

RHEA-AI

very positive

06/10/21 7:20 AM

OTC : ACHFF

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent

RHEA-AI

neutral

05/04/21 7:00 AM

OTC : ACHFF

covid-19

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has completed enrollment for its Phase II

RHEA-AI

neutral

04/15/21 7:00 AM

OTC : ACHFF

Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation Novel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists that prevent leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ

RHEA-AI

neutral

ACHFF Data

IndustryMiscellaneous Commercial Services
Websitehttp://www.archbiopartners.com
CeoRichard Gabriel Muruve
Security nameArch Biopartners, Inc.
Issue typecs
SectorCommercial Services
Sic code8731
Tags
- Advertising/Marketing Services
- Commercial Services
- Miscellaneous Commercial Services
Address545 King Street West
StateON
CityToronto
ZipM5V
CountryCA
Phone1.647.428.7031

About Arch Biopartners, Inc.

Arch Biopartners, Inc. is a portfolio based biotechnology company. It is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The company has five technology platforms which includes: AB569, MetaBlok, Arch Inflammation, Borg:Peptide-Solid Surface Interface and MetaMx. Arch Biopartners was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.